Early Blood Test Predicts Survival in Patients with Metastatic Prostate Cancer
A study shows that measuring CTCs at the time of metastatic prostate cancer diagnosis can predict survival and guide treatment decisions.
A study shows that measuring CTCs at the time of metastatic prostate cancer diagnosis can predict survival and guide treatment decisions.
A study investigating a single invitation to a PSA blood test to screen for prostate cancer found it had a small impact on reducing deaths.
Researchers have developed a blood test that can reliably detect NEPC and differentiate it from CRPC-adenocarcinoma.
Black patients seen by a precision medicine navigator were substantially more likely to receive genomic testing than those who were not.
Read MoreTo explore why prostate cancer disproportionately harms Black men, researchers looked to another disorder, diabetes, which alters metabolism.
Read MoreBiomarkers of significant prostate cancer that are detected in urine or blood tests are desperately needed to help reduce prostate biopsies.
Read MoreA new study demonstrated Decipher Prostate Genomic Classifier’s ability to guide personalized treatment for men with prostate cancer.Â
Read MoreQuest launched a prostate cancer biomarker test through its pathology business, AmeriPath, in collaboration with Envision Sciences.Â
Read MoreThe AI-based predictive model was able to identify patients with a predominantly intermediate risk for prostate cancer likely to benefit from short-term ADT.
Read MoreCleveland Diagnostics, a biotechnology company developing next-gen diagnostic tests for early detection of cancers, opened a new facility.
Read MoreAmerican Indian and Alaska Native men also experience disproportionately greater prostate cancer mortality compared to other racial/ethnic identities.
Read MoreThe accuracy of PSA in prostate cancer screening can be improved by accounting for genetic factors that are not associated with cancer.
Read MoreExperts argue that “test by request” have led to higher PSA testing and clear medical harm, with minimal benefit and inequity.
Read MoreLevels of PSA are low in healthy men but elevate in the presence of prostate cancer and other mentioned conditions.Â
Read MoreA new minimally invasive prostate biopsy procedure reduces the risk of infection, improves imaging for accuracy, and may increase cancer detection in a clinic setting.
Read MoreThe American Urological Association and Society of Urologic Oncology have released the 2023 clinical practice guideline on the early detection of prostate cancer.
Read MoreA new study informed use of PARP inhibitors beyond BRCA1/2-deficient tumors and reevaluated biomarkers for PARP inhibition in prostate cancer.
Read MoreA rapid test for advanced prostate cancer can quickly identify people with “actionable” gene variants eligible for new targeted therapies.
Read More